AstraZeneca Signs $205 Million Agreement to Provide Covid-19 Antibody Treatment in US
16 März 2021 - 9:12AM
Dow Jones News
By Joe Hoppe
AstraZeneca PLC said Tuesday that it has signed a $205 million
agreement to supply the U.S. with up to 500,000 additional doses of
its coronavirus antibody treatment, AZD7442.
The British pharmaceutical giant said the deal builds on an
agreement in October 2020 with the U.S. Department of Defense and
the Department of Health and Human Services to provide an initial
100,000 doses, with the option to acquire more.
The company had also made a separate agreement with the
Department of Defense to supply 100,000 doses, bringing the total
number of potential U.S. doses in 2021 to 700,000.
"The U.S. government's support is critical in helping accelerate
the development of AZD7442, which we believe will be an important
tool in the fight against Covid-19," Chief Executive Pascal Soriot
said.
The drug is currently being evaluated in late-stage trials in
more than 9,000 participants around the world. The company said the
agreement is contingent on receiving emergency use authorization
from the U.S. Food and Drug Administration, and that the total
value of current agreements with the U.S. government for supply and
development of the treatment in 2021 is around $726 million.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
March 16, 2021 03:57 ET (07:57 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
